Announcement

Collapse
No announcement yet.

Am J Physiol Heart Circ Physiol. COVID-19, ACE2 and the Cardiovascular Consequences

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • Am J Physiol Heart Circ Physiol. COVID-19, ACE2 and the Cardiovascular Consequences


    Am J Physiol Heart Circ Physiol. 2020 Mar 31. doi: 10.1152/ajpheart.00217.2020. [Epub ahead of print]
    COVID-19, ACE2 and the Cardiovascular Consequences.


    South AM1, Diz D2, Chappell MC3.

    Author information




    Abstract

    The novel SARS coronavirus SARS-CoV-2 pandemic may be particularly deleterious to patients with underlying cardiovascular disease (CVD). The mechanism for SARS-CoV-2 infection is the requisite binding of the virus to the membrane-bound form of angiotensin-converting enzyme 2 (ACE2) and internalization of the complex by the host cell. Recognition that ACE2 is the co-receptor for the coronavirus has prompted new therapeutic approaches to block the enzyme or reduce its expression to prevent the cellular entry and SARS-CoV-2 infection in tissues that express ACE2 including lung, heart, kidney, brain, and gut. ACE2, however, is a key enzymatic component of the renin-angiotensin-aldosterone system (RAAS); ACE2 degrades Ang II, a peptide with multiple actions that promote CVD, and generates Ang-(1-7) which antagonizes the effects of Ang II. Moreover, experimental evidence suggests that RAAS blockade by ACE inhibitors, AT1 receptor antagonists and mineralocorticoid antagonists, as well as statins enhance ACE2 that, in part, contribute to the benefit of these regimens. In lieu of the fact that many older patients with hypertension or other CVDs are routinely treated with RAAS blockers and statins, new clinical concerns have developed regarding whether these patients are at greater risk for SARS-CoV-2 infection, whether RAAS and statin therapy should be discontinued, and the potential consequences of RAAS blockade to COVID-19-related pathologies such as acute and chronic respiratory disease. The current perspective critically examines the evidence for ACE2 regulation by RAAS blockade and statins, the cardiovascular benefits of ACE2, and whether ACE2 blockade is a viable approach to attenuate COVID-19.



    KEYWORDS:

    ACE2; Angiotensin II; SARS-CoV-2; renin-angiotensn system; statins


    PMID:32228252DOI:10.1152/ajpheart.00217.2020

Working...
X